This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

7 Dec 2010

Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib

Pfizer Inc. announced that a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemiawho were treated with bosutinib (39 percent) experienced a major molecular response.

Related News